ELDN
HEALTHCAREEledon Pharmaceuticals Inc
$3.80+0.02 (+0.53%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ELDN Today?
No stock-specific AI insight has been generated for ELDN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.35$4.60
$3.80
Fundamentals
Market Cap$293M
P/E Ratio—
EPS$-0.52
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume2.0M
Avg Volume (10D)—
Shares Outstanding77.2M
ELDN News
20 articles- EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes DrugYahoo Finance·May 1, 2026
- NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026Yahoo Finance·Apr 30, 2026
- Here is Why Eledon Pharmaceuticals (ELDN) is an Unstoppable Stock That Could Double Your MoneyYahoo Finance·Apr 20, 2026
- NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech ConferenceYahoo Finance·Apr 20, 2026
- Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial ResultsYahoo Finance·Mar 19, 2026
- Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago MedicineYahoo Finance·Mar 16, 2026
- Eledon Pharmaceuticals Touts Tegoprubart Safety in BESTOW Kidney Transplant Data at Leerink ConferenceMarketbeat·Mar 15, 2026
- Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver TransplantationYahoo Finance·Mar 10, 2026
- NewcelX and Eledon partner for NCEL-101 programmeHospitalmanagement·Mar 10, 2026
- NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 DiabetesYahoo Finance·Mar 9, 2026
- Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare ConferenceYahoo Finance·Mar 4, 2026
- Eledon Pharmaceuticals Highlights BESTOW Data, Phase III Plans and FDA Timeline for “Tego” at ConferenceMarketbeat·Feb 13, 2026
- Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026Yahoo Finance·Feb 5, 2026
- Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter SymposiumYahoo Finance·Jan 23, 2026
- Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 OutlookYahoo Finance·Jan 8, 2026
- Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare ConferenceYahoo Finance·Dec 1, 2025
- Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago MedicineYahoo Finance·Nov 18, 2025
- Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial ResultsYahoo Finance·Nov 14, 2025
- Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·Nov 12, 2025
- Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·Nov 11, 2025
All 20 articles loaded
Price Data
Open$3.79
Previous Close$3.78
Day High$3.89
Day Low$3.71
52 Week High$4.60
52 Week Low$1.35
52-Week Range
$1.35$4.60
$3.80
Fundamentals
Market Cap$293M
P/E Ratio—
EPS$-0.52
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume2.0M
Avg Volume (10D)—
Shares Outstanding77.2M
About Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing drugs for patients living with autoimmune diseases and amyotrophic lateral sclerosis (ALS) who require organ or cell transplantation. The company is headquartered in Irvine, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—